FOLDNEUTRAL

Revenue Growth (YoY)

23.7%

Higher than 90% of Healthcare sector peers

Updated 94h ago

Sector Performance

90th percentile

FOLD

23.7%

Sector Median

6.2%

Sector Avg

3.8%

📊

Deep Analysis

Revenue growth year-over-year (YoY) compares a company's current-period revenue to the same period one year earlier; Amicus Therapeutics' 23.7% increase means its sales expanded by nearly a quarter over the past twelve months.

This far exceeds the healthcare sector median of 6.2%, placing the company in the 90th percentile among its peers. The trend data for this metric is not available — the year-over-year change is listed as N/A, the quarter-over-quarter change is N/A, and no historical values beyond the current figure of 23.7% are provided. With only a single data point showing a high current level but no trend direction, an investor cannot assess whether growth is accelerating, stable, or decelerating, making the risk or opportunity ambiguous. The high absolute growth rate is a positive signal, but the lack of trend context limits its usefulness in forming a clear view. This metric supports the overall NEUTRAL verdict because the strong growth level is countered by insufficient historical data to confirm sustainability or momentum.

Frequently Asked Questions

What does the Revenue Growth (YoY) tell investors about FOLD?

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.

How is the Revenue Growth (YoY) calculated?

Revenue Growth (YoY) is calculated as: (Revenue_t - Revenue_t-4) / Revenue_t-4.

How does FOLD's Revenue Growth (YoY) compare to its sector?

FOLD's Revenue Growth (YoY) of 23.7% compares to a Healthcare sector median of 6.2%, placing it in the 90th percentile.

Who are FOLD's closest peers by Revenue Growth (YoY)?

The closest Healthcare peers by Revenue Growth (YoY) include: AMGN (5.8%), CPRX (5.6%), HIMS (3.8%), BAX (2.9%), BMY (2.6%).

The Formula

(Revenue_t - Revenue_t-4) / Revenue_t-4

Why It Matters

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.